Drug
Cangrelor
Cangrelor: highest development phase Post-Market, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cangrelor NCT03247738 | Post-Market | ST Segment Elevation Myocardial Infarction |
Latest
No recent events.
Follow Cangrelor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.